The suppressor of cytokine signaling 2 (SOCS2) acts as substrate recognition subunit of a 13 Cullin5 E3 ubiquitin ligase complex. SOCS2 binds to phosphotyrosine-modified epitopes 14
Introduction 31
Cytokines are small glycoproteins that play important roles in the differentiation, 32 development and function of lymphoid and myeloid cells 1 . The Janus kinase (JAK) -33 signal transducer and activator of transcription (STAT) signaling pathway plays a critical 34
role enabling cells to respond to specific cytokines by regulating gene expression. 35
Suppressor of cytokine signalling (SOCS) proteins, which comprise of cytokine inducible 36 SH2-containing protein (CIS) and SOCS1 -SOCS7, negatively regulate cytokine 37 receptors and inhibit the JAK-STAT signaling pathway 2 . 38
39
SOCS proteins share a conserved domain architecture comprising of an N-terminal 40 extended SH2 subdomain (ESS) that functions as a bridge at the interface between the 41 SH2 domain and the SOCS box enabling ubiquitination of captured substrate 3-5 , followed 42 by a central Src-homology 2 (SH2) domain that recognizes a phosphotyrosine (pY) 43 containing sequence 6 , and a C-terminal SOCS box that interacts with the adaptor 44
ElonginB-ElonginC complex (EloBC) 7-9 . All SOCS proteins bind to EloBC and recruit 45
Cullin5 with high specificity, forming different SOCS-EloBC-Cullin5-Rbx2 (CRL5 SOCS ) E3 46 ligases that catalyse ubiquitin transfer and subsequent proteasomal degradation of 47 specific substrates, as a mechanism to regulate diverse biological processes [10] [11] [12] [13] . SOCS 48 proteins serve as substrate recognition modules that impart substrate specificity to each 49 CRL5 SOCS E3 complex. 50 51 Expression of SOCS proteins is induced by cytokine stimulation. Upon cytokine binding, 52
the oligomerized receptors activate the JAK family kinases that phosphorylate specific 53 tyrosine residues on the receptor, including the docking sites for the STAT proteins. The 54
docked STAT proteins are sequentially phosphorylated, they dimerize and translocate into 55 the nucleus, initiating gene transcription of several downstream proteins including the 56 SOCS proteins. SOCS proteins suppress the JAK-STAT pathway via three distinct but 57 often concomitant mechanisms: 1) KIR mediated direct JAK inhibition 3, 14 ; 2) Blocking 58 STAT activation by competing for receptor pY sites 15 ; 3) Targeting the receptor for 59 proteasomal degradation via SOCS E3 ligase activity 16, 17 . Some of the SOCS-substrate 60 interactions have been structurally characterized, including SOCS1-JAK 18 , SOCS3-gp130 61 4,19 , SOCS3-gp130-JAK2 20 and SOCS6-cKit 21 . 62 63 SOCS2, one of the members of the SOCS family, is implicated in the disorders in immune 64 system, central nervous system and cancer, and is thus emerging as a promising target for 65 cancer therapies [22] [23] [24] [25] . SOCS2 has been shown as the primary suppressor of growth 66 hormone (GH) pathway where a gigantism phenotype was observed in a SOCS2 -/mice 26 . 67 Paradoxically, the SOCS2 overexpressed transgenic mice also led to the same phenotype 68 27 . Attenuation of GHR signalling relies on two phosphorylation sites at GHR that are 69 recognised by SOCS2 16, 28 . The pY487 site of GHR interacts with CRL5 SOCS2 E3 ligase 70 that targets the GHR for ubiquitination and proteasomal degradation 16 . A downstream 71 pY595 site interacts with SOCS2, STAT5b and SHP2 (SH2 domain-containing 72
phosphatase 2), enabling SOCS2 to inhibit the signaling by blocking this receptor site from 73
STAT5b 15, 27, 29, 30 . Nonetheless, deletion of both sites is required to remove the inhibitory 74 effect of SOCS2 on the GH signaling 16, 28 . Analysis of the binding affinity of SOCS2 for 75 these two phosphorylation sites of GHR reveals that the pY595 region exhibits a higher 76 affinity towards SOCS2 (K D = 1.6 μM) compared to pY487 region (K D = 11.3 μM) 5,31,32 . An 77 11-mer phosphorylated peptide spanning the pY595 region of GHR was sufficient to pull 78 down the whole CRL5 SOCS2 complex from human cell lysates 31 as well as CIS, the closest 79 homologue to SOCS2 from the same family, which plays a role in anti-tumor immunity 80 controlling the differentiation of CD4 T helper cell, and the IL-2 and IL-4 response 31, 33 . In 81 addition to GHR and CIS, other substrates have been identified to interact with SOCS2, 82
including the erythropoietin receptor (EpoR) at pY426 34 , the leptin receptor at pY1077 35 , 83 the epidermal growth factor receptor 36 and the insulin-like growth factor-I receptor 37 . The 84 first crystal structure of SOCS2-ElonginB-ElonginC (SBC) was reported in 2006 32 , 85 however the structural basis for substrate recognition to SOCS2 has yet remained elusive. 86 87 Here, we determine the first co-crystal structures of SBC in complex with phosphorylated 88 epitope peptides from its physiological targets GHR and EpoR. Our structures reveal the 89 peptides are accommodated in an extended conformation to capture specific interactions 90 with SOCS2. A key flexible region of SOCS2, known as the BG loop, is defined in the 91 electron density for the first time and shown not to contact the bound substrates. Structural 92 analyses supported by biophysical and mutagenesis investigations allowed identification of 93 hotspot residues on the substrate degrons and functional elucidation of disease-relevant 94 single nucleotide polymorphisms (SNPs) of SOCS2. Our findings provide fresh insights 95
into the molecular recognition and selectivity between SOCS2 and target substrates, and 96 provide an important template for future structure-guided ligand design. 97
98

Results
99
To elucidate the molecular basis of substrate recognition by SOCS2, we subjected the 100 SOCS2-ElonginB-ElonginC (SBC) complex to extensive co-crystallization trials with 11-101 residue phosphopeptides of either EpoR or GHR that span the regions surrounding Tyr426 102
and Tyr 595 region, respectively. The affinity of SBC for EpoR_pY426 (K D of 6.9 μM) and 103
GHR_pY595 (K D of 1.1 μM) was measured by isothermal titration calorimetry (ITC), and 104 found to be consistent with the literature 31,32 ( Figure S1 ). Attempts to co-crystallize wild-105 type SBC protein constructs 31,32 with either GHR or EpoR peptide were unsuccessful as 106 resulting crystals only diffracted poorly. To improve crystal quality, we engineered a cluster 107 of three mutations K115A/K117A/Q118A on SOCS2 that was predicted to significantly 108 reduce surface conformational entropy and thermodynamically favor crystal packing 38 (Figure 1a ). Electron density for nine out of eleven non-terminal 117
EpoR_pY426 residues are well defined in the structure (Figure 1b) . A classic SH2 domain-118 pY peptide interaction is observed where the pY residue is anchored at the pY pocket and 119 the flanking residues are extending across the SH2 domain. The pY residue is tightly 120 locked by an intricate hydrogen-bonding network formed by residues Arg73, Ser75, Ser76, 121
Thr83 and Arg96 of SOCS2 ( Figure 1c ). Additional hydrogen bonds are formed along the 122 backbone of EpoR_pY426 peptide from Glu(-1) to Leu(+3) with SOCS2 residues Thr93, 123
Asn94, Asp107 and one structural water ( Figure 1d ). Multiple hydrophobic interactions 124 also support the binding of EpoR_pY426 C-terminal residues, Ile(+2), Leu(+3) and Pro(+5) 125 that are well accommodated within a hydrophobic patch created by Leu95, Leu106, 126
Ser108, Ile109, Val112, Leu116 and Leu150 of SOCS2 ( Figure 1e ). 127 protomers via the backbone atoms of the EloB subunit reveals a hinge motion between the 135 SH2 domain and the SOCS box ( Figure S2 ). Such motion is a common feature in SOCS 136 box and F-box containing proteins and it has been shown to be important as it facilitates 137 accurate orientation and positioning of a target substrate protein relative to the 138 multisubunit CRL complex 39, 41 . Contrary to the SBC-EpoR complex, which contains a 139 single copy of peptide per SH2 domain, two copies of GHR_pY595 peptides were found 140 binding per SH2 domain of SOCS2 (giving a total of four copies within the asymmetric 141 unit). The two peptides run in an anti-parallel direction relative to each other across the 142 SH2 domain, with well-defined electron density surrounding them both (Figure 2a ). One of 143
the peptides (referred to as peptide A hereafter) binds to SH2 domain in a canonical 144 manner, where the pY is recognized by the positively charged pY pocket between the 145 central β strands and αA ( Figure 2b ). In contrast, the second peptide, peptide B, has its pY 146 residue exposed to solvent and interacting only with His149 of SOCS2 ( Figure 2b ). 147 148
Specific interaction of the GHR_pY595 phosphopeptide 149
The unusual simultaneous binding observed for the GHR substrate peptide to SOCS2 150 SH2 domain is imparted mainly by the region comprising Ser(+2) to Val(+6) from each 151 peptide, which pair such that they form an anti-parallel beta sheet ( Figure 2c ). Extensive 152 hydrogen bonds are formed between the backbone of the two peptides and backbone 153 residues of SOCS2 and structural waters ( Figure 2c ). Further hydrophobic interactions 154 appear to reinforce the binding, which impart specificity for GHR. The Ile(+3) and Ile(+5) of 155 peptide A and peptide B settle in a hydrophobic patch of the SH2 domain formed by 156
Leu95, Leu106, Ser108, Leu116 and Leu150 (Figure 2d ). Another hydrophobic interaction 157 that is distinct in SBC-GHR compared to SBC-EpoR is that formed by the side chain of 158 Val(-3) of peptide A, that nicely fits into a hydrophobic pocket comprising of Thr88, Ala90, 159
Thr93, Leu95 and Val148 from SOCS2 (Figure 2e ). In the SBC-GHR structure, a cobalt 160
ion is modeled at a positive peak that disappeared only at 21 σ level in the unbiased Fo-Fc 161 electron density map. This cobalt ion satisfies the formation of an octahedral coordination 162 geometry with the side chains of His(+4) of peptide B, His149 of SOCS2 and with three 163 surrounding water molecules ( Figure 2f ). SOCS2 is known to recognize two GHR binding sites at regions around pY487 and pY595, 167
respectively. We therefore hypothesized that the two copies of the GHR peptides bound in 168 the crystal structure might mimic a physiological folded conformation of GHR, presenting 169 each of the phosphorylated sites bound simultaneously to SOCS2. To test this hypothesis, 170
we utilized an 11-residue GHR_pY487 phosphopeptide (NIDFpYAQVSDI, K D of 2.3 μM by 171 ITC, Figure S1 ), mixed with the GHR_pY595 peptide and SBC in equimolar 1:1:1 ratio for 172 co-crystallization. In this crystal structure (hereafter referred to as SBC-GHR 2 ), still two 173 copies of the GHR_pY595 peptide, but no GHR_pY487, are observed bound, yielding a 174 structure very similar to the previous SBC-GHR structure ( Figure S3 ). However, an 175
important observation in SBC-GHR 2 compared to our other co-crystal structures was that 176 the regions of SOCS2 corresponding to residues 134-162 is now fully visible in the 177 electron density. This is unprecedented, and the first time this region, also called BG loop 178 is structurally defined in full. The BG loop connects the βB and βG strands of an SH2 179 domain ( Figure 3a ). The first part of the BG loop (residues 134-148 in SOCS2) differs in 180 length and sequence among SOCS proteins ( Figure 3b ). We refer herein to this more 181 variable region as the "specificity BG loop", because its conformation, together with the 182 configuration of the adjacent EF loop, governs accessibility of the pY binding pocket and 183 contributes to substrate specificity in SH2 domains 42 . A particular region in the middle of 184 the specificity BG loop (residues 136-145) is found to be disordered in all previously 185 determined SOCS2 structures (PBD code, 2C9W, 4JGH and 5BO4) as well as our other 186 co-crystal structures SBC-GHR and SBC-EpoR. In this SBC-GHR 2 structure, the BG loop 187
is in an open conformation stabilised by crystal contacts, Pro140 (BG loop) to Arg186 188 (SOCS box) and Pro140 (BG loop) to Ile90 (EloB), as clearly defined by the unbiased omit 189 map at this region ( Figure 3c , Table 1 ). 190
191
Conformational changes of the EF and BG loop 192
The configuration of the EF and BG loops play an important role in governing the 193 accessibility of the binding pocket and specificity toward ligand binding 42 Figure 4b ), or rearranges itself to allow a specific 199
interaction with EpoR_pY426 ( Figure 4c ). This specific interaction between EF loop and 200
EpoR_pY426 involves hydrophobic interactions between Ile109 and Val112 of SOCS2, 201
Val112 of a SOCS2 symmetry mate, and Pro(+5) of EpoR_pY426, resulting in a 202 differential binding mode from GHR_pY595 to SOCS2. The BG loop of SOCS2 is 203 observed to be in an open conformation in SBC-GHR 2 and SBC-EpoR (disordered) 204 structures. A superimposition of the two substrate complex structures suggest that the BG 205 loop opens up further in SBC-GHR structure to accommodate two GHR peptides ( Figure  206 4d). 207 208
Biophysical characterization of specificity between GHR_pY595 and SOCS2 209
To evaluate the specificity of the protein-peptide interaction in solution, we designed 210 single-point mutations on the peptide first, and compared their binding to wild-type peptide 211
by two orthogonal biophysical methods: a direct binding assay using SPR (SBC 212 immobilized on the chip) and 19 F ligand-observed displacement NMR assays. In the 19 F 213 NMR displacement assay, the fluorine signal of a purposely-designed reporter ligand (also 214 referred to as spy molecule) was monitored as a mean to quantify the extent of the 215 competition between the tested peptides and the spy molecule. A Carr-Purcell-Meibom-Gill 216
(CPMG) pulse sequence was applied to estimate the spin-spin relaxation time (T 2 ) of the 217 spy molecule in the absence and presence of protein 43-45 . By adding competitor to disrupt 218 the protein-spy interaction, the binding affinity of a competitor can be calculated based on 219 the degree of displacement of the spy 46,47 . The spy molecule used in our assay is 220 phosphate 3, a fluorinated pY analogue that specifically binds to the pY pocket with a K D of 221 50 μM (Scheme 1, and Figure S4 ). The two assays were found to be robust and reliable 222 where the measured K D and K i values at R 2 of 0.74 correlation ( Figure S5 ). 223
224
First, we focused on the unique interaction formed by Val(-3) of GHR_pY595, which 225
inserts into a small hydrophobic cavity of SOCS2 (Figure 2e ). This interaction was 226 investigated by mutating Val(-3) in the GHR peptide to Tyr and Arg, as representative 227 bulky and charged residues, respectively. We hypothesized this structural change would 228 disrupt the fit at this small hydrophobic pocket. Mutant V(-3)R exhibited between a 6-and 229 a 14-fold loss of binding affinity to SBC, depending on the assay, suggesting the charged 230 group strongly disrupts the interaction (Table 2) . By contrast, the V(-3)Y was less 231 disruptive, with only a two-fold loss in affinity. 232
233
Next, to map the relative importance and contribution of each individual amino acids to the 234 binding affinity with SBC, alanine scan of the substrate peptides was invoked. The peptide 235
sequences were designed such that individual amino acids were separately mutated into 236 alanine except pY, which is known to abolish binding if mutated even to unphosphorylated 237 Y 31 . The resulting library comprised of the original wild-type sequences, ten derivatives 238 from GHR_pY595 and nine from EpoR_pY426, and was characterized in parallel using 239 SPR and 19 F NMR competition assay (Table 3) . Alanine substitution at pY(-3), pY(-1), 240 pY(+3) and pY(+4) of the GHR_pY595 resulted in at least two-fold weakened binding 241
(increase in K D ) compared to the wild type. In contrast, a similar 2-fold weakening in 242 binding affinity was observed in the EpoR_pY426 peptide upon alanine substitution at pY(-243 1), pY(+2) and pY(+3). These results are consistent with observations from our crystal 244 structures that peptide-SOCS2 binding is mediated by hydrophobic interaction including 245 pY(-3), pY(+3) and pY(+5) on the GHR_pY595 and pY(+2) and pY(+3) on the 246
EpoR_pY426. The binding affinity for each peptide also dropped by at least two-fold with 247
Ala substitution at pY(-1) position, indicating the importance of the residue just upstream of 248
pY. 249 250
SNPs study 251
Several single nucleotide polymorphisms (SNPs) on SOCS2 are reported in the Catalogue 252 of Somatic Mutation in Cancer database (COSMIC) as potentially linked to cancers such 253
as tumours of the lung, breast, and pancreas 48 . We thus next decided to characterize the 254 interaction of selected SNP SOCS2 mutants with substrate peptides GHR_pY595, 255
EpoR_pY426 and GHR_pY487 by SPR. Inspection of our SBC co-crystal structures 256 guided us to select five known SNPs: N94D, R96L, R96Q that are located in the pY-pocket 257
and involved in direct recognition of pY; L106V that is highly conserved at the hydrophobic 258
SH2 domain involving in substrate interaction; and C133Y that participates in the SH2 259 hydrophobic core ( Figure 5a ). All mutant proteins expressed and purified similarly to wild-260 type, and the mutations did not appear to affect the structural integrity and solubility of the 261 constructs, as observed by 1 H NMR ( Figure S6 ). 262
263
The L106V and C133Y mutations did not affect binding affinities compared to wild type 264 The BG loop of SOCS2 had not been fully revealed in previous published structures. Here, 293
we report an open conformation BG loop, which is contradictory to other SOCS structures 294 with bound peptides, for example SOCS3:gp130 and SOCS6:c-kit 19,21 . In the SOCS3 and 295 SOCS6 peptide-bound structures, the BG loop folds up as a hairpin interacting with the 296 substrate peptide, forming a triple-stranded β sheet structure (Figure 7a substrates could contribute to its relatively greater promiscuity to multiple substrates. 326
327
The observation of the dual-peptide binding mode to SOCS2 was unexpected, however is 328 not unprecedented with SH2 domains, as reported previously with the tyrosine 329 phosphatase SHP-2 50 . In the co-crystal structure of SHP-2:pY peptide solved by Zhang et 330
al., one pY of the peptide is recognized at the pY pocket and the other one is solvent 331 exposed as in our structures described herein. Besides, two peptides run antiparallel to 332 each other and form an antiparallel four-stranded β sheet with BG loop. Zhang et al. 333 suggested that the dimerization of peptide binding in SHP-2 requires at least one pY 334 containing peptide and demonstrates enhanced binding affinity to protein. For our SBC-335 GHR structure, despite preparing several protein-peptide samples for co-crystallization at 336 1:1 molar ratio, all dataset collected from crystals were consistent with a 1:2 (protein-337 peptide) binding mode. In both cases, the binding of the non-canonical binding peptide 338 relies on hydrophobic interaction with the SH2 domain hydrophobic core, and backbone to 339 backbone interaction with the canonical binding peptide and protein (Figure 6d ). The 1:1 340 binding mode for EpoR could be justified by the presence of Pro(+5) in EpoR, that acts as 341 a strand breaker and prevents backbone to backbone interaction with the second peptide. 342
Indeed, from the alanine scan (Table 3) , we observe that when Pro(+5) is replaced by 343 alanine, the affinity improves -implying the possibility of secondary peptide binding. 344
345
We put forth two distinct models that might explain the dual peptide recognition mode and 346 its role in specific tuning of GHR signaling response. First, a "cis" recognition mode, where 347
the GHR tail folds back as a hairpin structure presenting two binding epitopes around 348 distinct phosphorylation sites (e.g. pY487 and pY595) for recognition ( Figure 8a) . 349
However, the crystallography data from our follow-up experiment as described in the SBC-350 GHR 2 structure is not consistent with this hypothesis, as two instances of the pY595 351 peptide were found bound despite a molar ratio of 1:1 for pY487 and pY595 peptides 352
being present in the co-crystallization buffer. However, we cannot exclude that 353 simultaneous recognition of the two distinct epitopes would require a loop of the same tail 354 twisting back onto itself to enhance the binding affinity of second epitope. Alternatively, we 355 envisage a "trans" recognition mode, where SOCS2 recognize two separate receptor tails 356 of the activated dimerized GHR receptors at the cell membrane (Figure 8b ). SOCS2 might 357
additionally play a role as scaffold bringing two substrates in close proximity, for example 358 by recruiting one instance of phosphorylated substrate to assist the binding of un-359 phosphorylated one for post-translational modification. This mechanism evokes potential 360 similarities with some phosphodegrons which require two sites to be phosphorylated, 361 utilizing a first kinase to "prime" phosphorylation events, followed by a second kinase for 362 follow-on phosphorylation 51 . An example of such a mechanism is the β-catenin 363 degradation mediated by the β-TrCP 52 . Further biophysical investigation is warranted to 364 address the extent to which these potential mechanisms might be invoked for SOCS2 365 function. 366 367 SOCS2 is an attractive therapeutic target due to its links to cancer, diabetes, neurological 368 and inflammatory diseases 23,24,53-57 . Breast, lung, liver and ovarian cancer have been 369 correlated with down-regulation in SOCS2 58-63 . In addition to the JAK-STAT pathway, a 370 recent study has identified the involvement of SOCS2 in the NF-κB (nuclear factor kappa-371 light-chain-enhancer of activated B cells) pathway that regulates the immune and 372 inflammatory responses 64,65 . NF-κB is found to be constitutively activated in many types of 373 cancer and influences a diverse array of pro-tumorigenic functions, therefore NK-κB plays 374 an pivotal role in cancer initiation and progression 66 . SOCS2 negatively regulates TNFα 375 induced NF-κB activation by targeting NDR1, a serine-threonine kinase, for proteasomal 376 degradation. Hence SOCS2 deficiency may lead to an increased level of NDR1, which 377 was is reported to result in aggressive behaviour of PC3 prostate cancer cells 64 . These 378 evidences highlight the potential in targeting SOCS2 for drug discovery for inflammation 379 and cancer biology. We have revealed structural insights into the SOCS2-peptide 380
interactions by X-ray crystallography and identified hotspot using alanine scanning, 381 mutation study and SNPs study. This information provides a template to guide the 382 structure-based rational design of SOCS2 ligands that are instrumental in the development 383 of novel chemical tools to address biological question of SOCS2, and in the quest for 384 novel small molecule ligands binding to SOCS2 as potential therapeutics. SOCS2 binders 385
at the pY binding pocket can be used as inhibitors of the CRL5 SOCS2 , which would be 386 expected to prevent degradation of target substrate receptors, thus prolonging the activity 387 of cytokine signaling pathway and upregulating expression of endogenous STAT5b-388 responsive gene expression. In a distinct application, a SOCS2 binder could be used as 389 E3 ligase ligand handle for designing new chemical degraders to hijack SOCS2 CRL 390 activity and trigger the degradation of unwanted proteins inside cell 67-69 . This approach, 391 also known as proteolysis targeting chimeras (PROTACs), offers the advantage of 392
inducing rapid and selective intracellular depletion of the target protein, as opposed to 393 mere blockade of a single interaction or activity, which pairs more closely to genetic target 394 validation and often results in greater maximal efficacy of intervention in a signaling 395 pathway. PROTAC-mediated protein degradation has been shown to occur at very low 396 compound concentration (pM to nM range) also potentially allows targeting of intractable 397
protein targets that are beyond the reach of conventional small-molecule approaches that 398 require full occupancy of a target binding site e.g. receptor antagonists and enzyme 399 inhibitors. A limited set of E3 ligases have been targeted so far for PROTACs, notably VHL 400 70,71 and cereblon 72,73 , so extending the approach to other ligandable E3 ligases would be 401
an important advance to the field. The usage of SOCS2 binders for PROTACs may be 402 limited to SOCS2 expressing cells, however, this provides an additional layer of tissue 403 specific degradation of target proteins. PROTACs designed using SOCS2 binders as 404 recruiters would be ideal for degrading targets specifically in cells affected with leukemia 405
and gastrointestinal sarcoma which have been recorded to have upregulated SOCS2 406 expression 87 . Low levels of SOCS2 in other normal tissues would help minimize toxicity. 407
In addition, a pan-SOCS recruiting PROTACs would help diversifying the target tissue 408 range. Our peptide-bound co-crystal structures suggest that SOCS2 might be ligandable 409
and provide a blueprint for the rational structure-guided design of novel SOCS2 inhibitors 410 and SOCS2 ligand handles for PROTACs. 411 412 413 414
Materials and Methods 415
Cloning and protein expression 416
The human SOCS2 (amino acids 32 -198) and the ElonginB (amino acids 1 -104) and 417
ElonginC (amino acids 17 -112) plasmids were used for protein expression as previously 418
reported 39 , and as templates for mutagenesis. SOCS2 mutants with N94D, R96L, R96Q, 419 L106V or C133Y mutation were introduced using a PCR-based method site-directed 420 mutagenesis. SOCS2 wild type and mutants were co-expressed and purified as previously 421 described 31,39 . 422 423
Crystallization and structure determination of SBC-GHR 424
To improve crystallization, surface entropy reducing mutations were introduced into 425 detector. The column used was a Waters XBridge column (50 mm × 2.1 mm, 3.5 µm 486
particle size) and the compounds were eluted with a gradient of 5−95% acetonitrile/water 487 + 0.1% formic acid over 3 min. Preparative HPLC was performed on a Gilson Preparative 488
HPLC System with a Waters X-Bridge C18 column (100 mm x 19 mm; 5 µm particle size) 489 and a gradient of 5 % to 95 % acetonitrile in water over 10 min, flow 25 mL/min, with 0.1 % 490 formic acid in the aqueous phase. A solution of the compound 2 (80 mg, 0.24 mmol) and DIPEA (85 µL, 0.48 mmol) in DCM 521 (2 mL) was cooled to -78 °C, and trifluoroacetic anhydride (34 µL, 0.24 mmol) was added. 522
The reaction mixture was stirred 1h at -78 °C. After solvent evaporation the residue was 523 dissolved in acetonitrile (0.5 mL) and 2M HCl was added (2 mL). The mixture was stirred 524 at room temperature overnight until no presence of the starting materials was detected by 525
LC-MS. The solvents were evaporated and residue was purified by HPLC to afford 526 phosphate 3 (30 mg, 34%) as a white solid. 1 synthesised as described below. The peptides were cleaved with 2.5% triisopropylsilane 537 and 2.5% water in TFA. The crude peptides were isolated from the cleavage mixture by 538 precipitation with cold ether, dissolved in the mixture water/DMF=1/1 and purified by 539 preparative HPLC under the following conditions: Waters X-Bridge C18 column (100 mm x 540 19 mm; 5 µm particle size), gradient of 5-95 % acetonitrile in water over 10 min, flow 25 541 mL/min, with 0.1 % formic acid in the aqueous phase, UV detection at λobs = 190 and 210 542 nm). The poor soluble peptides were purified according to the literature procedure 84 To a solution of Fmoc-tyrosine (2 g, 5 mmol) in anhydrous THF (12 mL) N-550 methylmorpholine (540 µL, 5 mmol) and tert-butyldimethylsilyl chloride (740 mg, 4.9 mmol) 551 were added. After 15 min 4,5-dicyanoimidazole (1.8 g, 15 mmol) and 552 diisopropylphosphoramidite (3.4 mL, 10 mmol) were added and the reaction mixture was 553 stirred at room temperature for 4 h. After cooling to 0°C 70% tert-butyl hydroperoxide (2 554 ml, 15 mmol) was introduced. After stirring for 2 h at 0°C, 10% Na 2 S 2 O 5 (20 ml) was added 555
and stirring continued for one more hour. The product was extracted with ethyl acetate, 556
washed with a 5% solution of KHSO 4 , brine, dried over MgSO 4 , concentrated by rotary 557 evaporation under reduced pressure, and further purified by column chromatography on 558 silica gel using a gradient elution of 0% to 10% of MeOH in DCM to afford O-559 (dibenzylphosphono)-N-Fmoc-L-tyrosine (3g, 90%) as a pale yellow solid. NMR spectra 560
were in agreement with the published data 85 . 561 562
Isothermal titration calorimetry 563
Experiments were performed with ITC200 instrument (Malvern) in 100mM HEPES pH7.5, 564
50mM NaCl, 0.5mM TCEP at 298K stirring the sample at 750 rpm. The ITC titration 565 consisted of 0.4 μL initial injection (discarded during data analysis) followed by 19 of 2 μL 566 injections at 120 seconds interval between injections. The GHR_pY595 peptide 567 Experiments were performed using Biacore T200 instrument (GH Healthcare) in 20 mM 576 HEPES pH7.5, 150 mM NaCl, 1mM TCEP, 0.005 % Tween20 buffer at 10 °C. Biotinylated 577 wild type SBC and mutants were immobilized onto a chip surface and injected a series of 578 seven concentrations (0.08, 0.25, 0.7, 2.2, 6.7, 20 and 60 μM) of peptide across the 579 sensor surface for 60 sec contact time and 120 sec disassociation time at 30 μl/min flow 580 rate. Data analysis was carried out using Biacore Evaluation Software (GE Healthcare). All 581 data were double-referenced for reference surface and blank injection. The processed 582
sensograms were fit to a steady-state affinity using a 1:1 binding model for K D estimation. 583 584 19 F Spy NMR displacement 585
All NMR experiments were conducted using AV-500 NHz Bruker spectrometer equipped 586 with a 5 mm CPQCI 1H/19F/13C/15N/D Z-GRD cryoprobe) at 298 K. Spectra were 587 recorded using a CPMG pulse sequence that attenuates broad resonances with an 588 interpulse delay at 0.133 seconds for 80 scans. The transmitter frequency was placed 589 The Fo-Fc ligand omit map of the EpoR_pY426 peptide (green mesh) contoured at 2.0 σ 7 level to highlight densities for the EpoR_pY426 peptide (orange stick) (c) Hydrogen bond 8 interactions (dash) between the pY of EpoR_pY426 peptide (orange stick) and SOCS2 9 (green). (d) Hydrogen bond interaction (dash) between the EpoR_pY426 peptide (orange 10 stick), SOCS2 (green stick) and water (red sphere). (e) Hydrophobic interaction between 11
EpoR_pY426 peptide (orange stick) and SOCS2 (surface). Hydrophobic residues on 12 SOCS2 are colored in pink. 13
Figure 2. Structural and interaction detail of the SBC-GHR co-crystal 15
Two copies of GHR_pY595 were observed in the co-crystal. One copy is shown as peptide 16
A (yellow stick) and the other one as peptide B (cyan stick (a) Illustration of the "cis" recognition binding mode where the two binding sites on GHR, 90 pY487 and pY595, folded into a hairpin structure for SOCS2 binding. SOCS2 is shown in 91 white surface, the hairpin structure is illustrated by connecting the two peptides (yellow 92 cartoon) with red dash lines. (b) Illustration of the "trans" binding mode where SOCS2 93 (white surface) could grab two receptor tails (cyan and yellow dash line) at the same time 94
after dimerization of receptors at the membrane. 95 
